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Abstract. Plasmodium falciparum parasite life stages respond differently to antimalarial drugs. Sensitive stage-
speciﬁc molecular assays may help to examine parasite dynamics at microscopically detectable and submicroscopic
parasite densities in epidemiological and clinical studies. In this study,we compared the performance of skeleton-binding
protein 1 (SBP1), ring-infected erythrocyte surface antigen, Hyp8, ring-exported protein 1 (REX1), and PHISTbmRNA for
detecting ring-stage trophozoite-speciﬁc transcripts using quantitative reverse transcriptase polymerase chain reaction.
Markers were tested on tightly synchronized in vitro parasites and clinical trial samples alongside establishedmarkers of
parasite density (18S DNA and rRNA) and gametocyte density (Pfs25 mRNA). SBP1 was the most sensitive marker but
showed low-level expression in mature gametocytes. Novel markers REX1 and PHISTb showed lower sensitivity but
higher speciﬁcity for ring-stage trophozoites. Using in vivo clinical trial samples from gametocyte-negative patients, we
observed evidence of persisting trophozoite transcripts for at least 14 days postinitiation of treatment. It is currently not
clear if these transcripts represent viable parasites that may have implications for clinical treatment outcome or trans-
mission potential.
INTRODUCTION
In the peripheral blood of individuals infected with Plas-
modium falciparum, ring-stage trophozoites and mature ga-
metocytes can be microscopically observed and their
densities, directly determined, whereas mature trophozoites
and schizonts are sequestered to the microvasculature of
various organs1 and developing gametocytes accumulate in
the extravascular compartment of the bone marrow.2 Precise
quantiﬁcation of circulating parasite stages is necessary to
accurately assess stage-speciﬁc clearance3 by antimalarials
and could support the evaluation of treatment efﬁcacy4 in
clinical trials. Indeed, artemisinin-based combination therapy
(ACT), the ﬁrst-line treatment against P. falciparum malaria,
does not equally affect all malaria parasite developmental
stages: although it is highly active against asexual blood
stages responsible for malaria morbidity andmortality, it does
not clear mature stage gametocytes, which may persist after
treatment,5,6 often at densities below the range that is de-
tectable bymicroscopy, andmay allow posttreatmentmalaria
transmission tomosquitoes.7,8 On the other hand, primaquine
alone does not clear asexual parasites but is the only available
drug that can accelerate gametocyte clearance.9
Several highly sensitive molecular assays for detecting
P. falciparum parasites are currently available, including
qualitative and quantitative polymerase chain reaction (PCR)
targeting genomic DNA of the small subunit ribosomal RNA
genes (18S) for detection and quantiﬁcation of total circulating
parasite biomass.10,11 Detection of RNA by quantitative re-
verse transcriptase PCR (qRT-PCR) may further increase
sensitivity for highly transcribed genes and enable the speciﬁc
detection of different parasite developmental stages such as
gametocytes through detection of Pfs25 transcripts.12 This
strategy can also be applied for the detection of other parasite
life stages that are present in peripheral blood such as ring-
stage trophozoites. An obstacle for the identiﬁcation of in-
formative trophozoite markers is the low-level expression of
some candidate genes in gametocytes, which reduces stage
speciﬁcity. Circulating gametocytes that persist after malaria
treatment and express low-level trophozoite-speciﬁc tran-
scripts could jeopardize molecular assays that aim to specif-
ically detect asexual stage parasites and lead to incorrect
conclusions on the effect of antimalarials on asexual parasite
clearance. Ring-infected erythrocyte surface antigen (RESA)
was previously used as ring-stage trophozoite marker,13
whereasmore recently skeleton-binding protein 1 (SBP1) was
proposed as highly sensitive marker for ring-stage trophozo-
ites that is capable of detecting submicroscopic parasite
densities.14
In the current study, we set out to compare the per-
formances of previously reported ring-stage trophozoite
markers and identify novel trophozoite-speciﬁc transcripts
to establish molecular markers that can detect and quan-
tify low densities of ring-stage trophozoites. Targets were
validated using in vitro samples of synchronous early and
late ring-stage trophozoites and gametocytes and ﬁeld
samples from a recent clinical trial where children with
asymptomatic P. falciparum infections were treated with
ACT alone or in combination with a gametocytocidal dose
of primaquine.15
MATERIALS AND METHODS
In vitro stage-speciﬁc parasite samples. We obtained
trophozoites at early and late ring-stage and stage V game-
tocytes through synchronous asexual and gametocyte
culture in vitro. Plasmodium falciparum NF54 strain was
* Address correspondence to Teun Bousema, Department of Medical
Microbiology, Radboud University Medical Center, Geert Grooteplein
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maintained in a semiautomated culture system.16–18 Brieﬂy,
in vitro parasites were grown in Roswell Park Memorial In-
stitutemedium supplementedwith human serum (complete
medium) and 5% hematocrit. Medium was changed twice
daily and fresh human red blood cells were added (San-
quin). Asexual parasiteswere synchronized by the selection
of late ring-stage trophozoites and schizonts on a 63%
percoll density gradient, which was followed by a 5% sor-
bitol treatment, killing the remaining schizonts after 5 hours,
ensuring tight synchronization of parasites within a 5-hour
window. Samples containing trophozoites at early and late
ring stage were harvested 10 and 20 hours after percoll
synchronization, respectively. Gametocytes were syn-
chronized by allowing asexual cultures to grow just above
20% parasitemia, after which trophozoites and schizonts
were selected on a 63%percoll density gradient. Five hours
postsynchronization, 20 U/mL heparin was added to the
culture medium, preventing further invasion of merozoites;
thereby creating a 5-hour time window for gametocyte
development and terminating asexual multiplication. Ma-
ture stage Vb gametocyte samples were obtained at day 9
postsynchronization. Parasite samples were lysed in L6
buffer19 and extracted immediately or frozen at _80C until
further use. L6 buffer (5.25 M GuSCN, 50 mM Tris-HCl [pH
6.4], 20 mM EDTA, 1.3% [wt/vol] Triton X-100) was pre-
pared as described earlier.19
Selection of novel ring-stage trophozoite markers and
primer design and validation. Novel ring-stage trophozo-
ite markers were identiﬁed from a recent computational
approach to determine stage speciﬁcity of P. falciparum
transcripts,14 determining the ratio of early ring-stage tro-
phozoite expression over gametocyte expression. Among
the genes with the highest differential expression, we
selected potential targets speciﬁc to ring-stage trophozo-
ites that showed the highest expression levels in asexual
stages, and that had an intron (Supplemental Table 1).
In addition to these potential markers, we tested two pre-
viously reported ring-stage trophozoite markers, RESA
(PF3D7_0102200)20 and SBP114 by qRT-PCR. Primers were
designed in an intron-spanning fashion whenever possible
to avoid ampliﬁcation of genomic DNA while avoiding the
requirement for a digest step; multiple primer sets were
tested to select primers resulting in the most sensitive,
linear ampliﬁcation (Supplemental Table 2 and Figure 1).
FIGURE 1. Validation of markers on stage-speciﬁc in vitro culture materials: early ring-stage trophozoites, late ring-stage trophozoites, and
stage V gametocytes. Total parasitemia wasmeasured by targeting the (A) 18S DNA and (B) 18S RNA at the transcript level. (C) Gametocytemic
signal was quantiﬁed by targeting Pfs25. (D–G) Transcription level of early ring-stage trophozoite markers were used to quantify ring-stage
trophozoites. Presented is the dilution series of duplicate measurements of the Log10 parasites/mL (x axis) and the corresponding CT values
(y axis).
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Different primers targeting Pf18S RNA and DNA, Pfs25
mRNA, SBP1 mRNA, RESA mRNA, Hyp8 mRNA, ring-
exported protein 1 (REX1) mRNA, and PHISTb mRNA
(Supplemental Table 3) were tested on strictly synchronized
in vitro cultured asexual stage parasites (early and late ring-
stage trophozoites) and stage V gametocytes.
Ampliﬁcation efﬁciency and limit of detection of the primers
wereassessedbycloning thePCR-ampliﬁedproducts into the
pTOPO-TA cloning vector (Invitrogen, Thermoscientiﬁc,
Boston, MA) by strictly following the manufacturer’s pro-
tocol (Supplemental Figure 1 and Table 1). Assay-speciﬁc
control plasmids were run in each plate with the respective
template inserted for Pf18S RNA and DNA, Pfs25, and
SBP1 when the in vivo clinical trial samples were tested for
the respective targets.
Nucleic acid extraction, cDNA synthesis, and qRT-
PCR methods. Total nucleic acids were extracted from
1-mL aliquots, containing 100-μL culturematerial + 900-μL L6
buffer19 using total Nucleic Acid Isolation Kit–High Perfor-
mance in a MagNAPure LC automatic extractor (Roche Ap-
plied Science, Basel, Switzerland) and eluted in 50-μL elution
buffer.
For targets for which we were not able to design intron-
spanningprimer sets, extracted total nucleic acidmaterial was
subjected to DNA digestion with the RQ1 DNaseI (Promega,
Madison, WI). cDNA was synthesized using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Carls-
bad, CA) following the manufacturers’ protocols. Digestion
efﬁciency was assessed by running a control during cDNA
synthesis without the reverse transcriptase enzyme to rule out
the possibility of ampliﬁcation of genomic DNA, especially for
targets that do not span intron regions.
All-circulating-stages parasite quantiﬁcation was per-
formed by quantitative PCR (qPCR) targeting the
P. falciparum 18S rRNA gene on total nucleic acids, using
primer and probe sequences described by Hermsen and
others21 with minor modiﬁcations. Brieﬂy, 5 μL of template
was run in 20 μL ﬁnal volume of a TaqMan Fast Advanced
master Mix (Applied Biosystems) that contained 110 nM
probe and 900 nM primer concentrations for 10 minutes at
95C and for 40 cycles at 95C for 15 seconds and 60C for
1 minute.
qRT-PCR on SBP1, RESA, and MAL13P1.61 Plasmodium-
exported protein (Hyp8) was run using 2.5 μL of tem-
plate (cDNA) in 20 μL ﬁnal volume of a GoTaq® qPCR
(Promega) mix that contained 225 nM primer concentration
for 10 minutes at 95C and for 40 cycles at 95C for
15 seconds and 60C for 1 minute and melt curve at 65C
for 5 seconds and 95C for 50 seconds. The same protocol
was followed for Pfs25 and Pf18S transcripts except that
only 1 μL of template (cDNA) was run in 20 μL ﬁnal volume
reaction mix. For PHISTb and REX1 targets, the protocols
used were similar to the Pfs25 protocol except that the
annealing temperatures were 58C and 56C for REX1 and
PHISTb, respectively.
Serial dilutions of strictly synchronized culture-derived
NF54P. falciparum early and late ring-stage trophozoites or
stage V gametocytes and/or assay-speciﬁc control plas-
mids with the respective template inserted at concentra-
tions of 106–101 copies of template/reaction were run in
duplicate in each plate for parasite quantiﬁcation. The
CFX96 Real-Time PCR Detection System (BIO-RAD,
Hercules, CA) was used for all assays.
Description of sample set from clinical trial. We tested
our set of molecular markers on RNA samples from a ran-
domized, double-blind, placebo-controlled trial in which
360 children with asymptomatic malaria in seasonal and
hyperendemic area of Burkina Faso were treated with
artemether–lumefantrine (AL, Coartem®; Novartis Pharma,
Basel, Switzerland), either alone or in combination with a
0.25 or 0.40 mg/kg primaquine dose.15 Treatment was di-
rectly observed and the trial provided evidence for faster
gametocyte clearance by microscopy, Pfs25 mRNA qRT-
PCR and Pfs25 mRNA quantitative nucleic acid sequence-
based ampliﬁcation in the primaquine arms. Finger prick
blood samples (50 μL) were collected on days 0, 2, 3, 7, 10,
and 14 and stored in 250 μL of RNAprotect® cell reagent
(QIAGEN, Hilden, Germany). Total nucleic acids were
extracted as mentioned earlier using a MagNAPure LC au-
tomatic extractor and total Nucleic Acid Isolation Kit–High
Performance (Roche Applied Science).
Dataanalysis.All analyseswere performedwith STATA 12
(StataCorp., College Station, TX) and Graph Pad Prism 5.0
(Graph Pad Software Inc., La Jolla, CA). Welch’s paired
Student’s t test was performed to compare asexual stage
parasite levels on different follow-up days (7–14). Levels of
the different asexual stage markers and the median density
of SBP1 on day 14 versus days 10 and 7 were compared
using two-sample Wilcoxon rank-sum (Mann–Whitney) test.
χ2 of Fisher’s exact test was used to evaluate the prevalence
of marker transcripts between the three treatment arms.
Spearman’s rank correlation coefﬁcient was used to assess
the relationship between asexual stage markers and the
gametocyte-speciﬁc Pfs25 qRT-PCR signal.
RESULTS
Selection of novel ring-stage trophozoite markers and
assay performances. In addition to the previously published
ring-stage trophozoit markers, RESA (PF3D7_0102200)13
and SBP1,14 we selected targets with the highest fold
change expression in asexual parasites and high ring-stage
TABLE 1
Correlation of markers of total parasite density or asexual parasite density with Pfs25 qRT-PCR signal
Marker Day 0 Day 2 Day 3 Day 7 Day 10 Day 14
18S DNA 0.27 (0.001) 0.55 (0.001) 0.55 (0.001) 0.31 (0.050) 0.67 (0.001) 0.49 (0.050)
18S RNA 0.14 (0.110) 0.91 (0.001) 0.84 (0.001) 0.35 (0.010) 0.82 (0.001) 0.62 (0.001)
SBP1 0.08 (0.355) _0.06 (0.589) _0.01 (0.955) _0.05 (0.820) _0.14 (0.525) 0.01 (0.974)
REX1 0.13 (0.124) 0.17 (0.278) _0.21 (0.380) _0.12 (0.729) _0.28 (0.401) 0.42 (0.201)
PHISTb 0.24 (0.010) 0.33 (0.198) 0.11 (0.629) _0.43 (0.397) _0.20 (0.580) NA
NA = not available; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; REX1 = ring-exported protein 1; SBP1 = skeleton-binding protein 1. Presented is the Spearman
correlation coefﬁcient and the P value in parenthesis.
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trophozoite expression levels: REX1 (PF3D7_0935900),22 a
PHISTb-exported protein (PF3D7_0424600),23 and GEXP07-
exported protein (Hyp8; PF3D7_1301700).24
Primers were developed for RESA, Hyp8, REX1, and
PHISTb; published primers for 18S DNA,21 18S RNA,12
SBP1,14 and Pfs2512 were used (Supplemental Table 3).
Ampliﬁcation efﬁciency of these primers was validated in
qRT-PCRs using a dilution series of constructs containing
the respective amplicon, and exceeded 91% based on
slope in all cases. The limit of detection was 1–10 copies/μL
for the different targets (Supplemental Table 2, not deter-
mined for REX1 and PHISTb). The cutoff value for positivity
was set at a point where the PCR lost its linear detection
range in more than 50% of the observations using both
culture material and constructs. We were unable to obtain
linear results for Hyp8 ampliﬁcation despite multiple attempts
to optimize conditions, disqualifying this target for ring-stage
trophozoite quantiﬁcation in the current study.
Validation of speciﬁcity and sensitivity of ring-stage
trophozoite and gametocyte markers using in vitro
material. The selected markers were validated on synchro-
nous asexual parasite and gametocyte cultures providing
early ring-stage trophozoites (10-hour postsynchronization),
late ring-stage trophozoites (20 hours), and mature gameto-
cyte (9 days) samples. Parasite concentrations between 106
and 101 parasites/mL were tested.
As expected, 18S DNA was detected in early ring-stage
trophozoites, late ring-stage trophozoites, and stage V ga-
metocytes with a limit of detection of 10 parasites/mL
(Figure 1A). 18S RNA was detected with similar transcript
FIGURE 2. Parasite carriage and stage composition of clinical malaria trial samples. Prevalence of (A–B) total parasites, (C) gametocytes, and
(D–F) asexual parasites in the three treatment arms is presented. Bar graphs indicate relative prevalence of the targets with regard to the baseline
signal onday0 vs. days2, 3, 7, 10, and14after initiationof treatment. (G–L) Boxplots in the lowerpanel indicate themedian, 25thand75thpercentile
parasite densities (Log10 parasites/mL) of the markers in the three treatments arms. Whiskers indicate the 5th and 95th percentiles. The three
treatment groups are presented on the x axis: AL = only artemether–lumefantrine, 0.25 = artemether–lumefantrine + 0.25 mg/kg primaquine, and
0.40 = Arthermer Lumefantrine + 0.40mg/kg primaquine. Shading of bars andwhiskers indicates days since the start of treatment (days 0–14), dark
to light colors. Error bars indicate the upper limit of the 95% conﬁdence interval of a binomial distribution.
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levels in early and late ring-stage trophozoites and game-
tocytes (Figure 1B). Pfs25 transcripts were detected
in stage V gametocytes25 at concentrations as low as
100 gametocytes/mL, whereas the highest ring-stage tro-
phozoite concentration (106 parasites/mL) also showed
Pfs25 transcript detection. RESA transcripts were more
abundantly present in ring-stage trophozoites but were
also detected in stage V gametocytes with a limit of de-
tection of;10,000 gametocytes/mL (Figure 1D), making it a
less suitable trophozoite-speciﬁc candidate. SBP1 was
detected in all parasite stages. Although transcript levels
were higher in ring-stage trophozoites, gametocyte con-
centrations ³ 10,000 gametocytes/mL had detectable
SBP1 transcripts in our in vitro assays (Figure 1E). REX1
was speciﬁc for ring-stage trophozoites; only the highest
concentration of gametocytes (106 parasites/mL) showed a
detectable signal for REX1 (Figure 1F). However, REX1 was
generally less sensitive for ring-stage trophozoite detection
compared with other markers with a limit of detection of
10,000 parasites/mL (Figure 1F). PHISTb shared a similar
speciﬁcity with REX1, detecting exclusively asexual parasites
(Figure 1G) and only parasite densities ³ 10,000 parasites/mL
had detectable ampliﬁcation.
Stage composition of parasites after artemether–
lumefantrine treatment with or without primaquine. The
complete set of molecular markers comprising 18S DNA,
18S RNA, Pfs25, SBP1, REX1, and PHISTb was used
to evaluate parasite carriage and stage composition in
samples from a clinical malaria trial.15 Prevalence of para-
site carriage was determined as the percentage of samples
for which a signal was detected with CT value below the
assay-speciﬁc cutoff, and density in positive samples was
estimated using in vitro standards. In Figure 2A and B,
prevalence of parasites was determined using qPCR and
qRT-PCR to detect genomic 18S DNA or 18S transcripts,
respectively. Parasite density according to 18S DNA or 18S
RNA signal is depicted in Figure 2G and H. Both prevalence
and density of parasites determined by 18S qPCR de-
creased rapidly after treatment although parasites were
detected in a proportion of study participants until day 14
(Figure 2A and G). In the groups receiving primaquine, 18S
qPCR parasite prevalence was lower at day 7 and beyond
(P < 0.01, Table 2).15 The 18S RNA transcripts suggest a
much higher prevalence of parasite-positive individuals
after treatment and decrease only on 14 days after initiation
of treatment with lower prevalence in the primaquine arms
(P < 0.001, Table 2). Gametocyte prevalence, determined by
the number of individuals positive for Pfs25 transcripts,
decreased following treatment in all arms with lower day 7
gametocyte prevalence in the primaquine-treated groups
(P < 0.001, Table 2). Gametocyte density in gametocyte-
positive samples did not decrease in a dose-dependent
manner (Figure 2I).
The expression of asexual stage-speciﬁc markers SBP1,
REX1, and PHISTb (Figure 2D–F) similarly indicate that a
fraction of the study population remains parasite positive
TABLE 2
Parasite prevalence by different molecular markers after initiation of treatment with artemether–lumefantrine alone or in combination
with primaquine
Markers Days since treatment
AL AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ AL vs. AL + 0.25 mg/kg PQ AL vs. AL + 0.40 mg/kg PQ
P values overall% (n/N) % (n/N) % (n/N) P values OR 95% CI P values OR 95% CI
Parasite prevalence by 18S DNA
3 60.5 (26/43) 63.3 (31/49) 50.0 (26/52) 0.783 1.13 0.48, 2.62 0.309 0.66 0.29, 1.48 0.3563
7 42.9 (18/42) 28.0 (14/50) 9.26 (5/54) 0.138 0.52 0.22, 1.23 0.001 0.14 0.05, 0.41 0.001
10 48.8 (20/41) 22.0 (11/50) 18.9 (10/53) 0.009 0.3 0.12, 0.73 0.003 0.24 0.10, 0.61 0.0037
14 36.6 (15/41) 12.2 (6/49) 11.1 (6/54) 0.009 0.24 0.08, 0.70 0.005 0.22 0.08, 0.63 0.004
Parasite prevalence by 18S RNA
3 97.7 (42/43) 98.0 (48/49) 98.1 (51/52) 0.926 1.14 0.07, 18.84 0.892 1.21 0.07, 20.00 0.9905
7 95.2 (40/42) 96.0 (48/50) 92.6 (50/54) 0.859 1.2 0.16, 8.90 0.598 0.62 0.11, 3.59 0.731
10 97.6 (40/41) 98.0 (49/50) 88.7 (47/53) 0.887 1.23 0.07, 20.21 0.139 0.2 0.02, 1.70 0.0761
14 97.6 (40/41) 81.6 (40/49) 63.0 (34/54) 0.041 0.11 0.01, 0.92 0.003 0.04 0.01, 0.33 0.001
Gametocyte prevalence by Pfs25
3 69.8 (30/43) 69.4 (34/49) 82.7 (43/52) 0.969 0.98 0.40, 2.39 0.141 2.07 0.79, 5.46 0.2091
7 47.6 (20/42) 22.0 (11/50) 14.8 (8/54) 0.011 0.31 0.13, 0.76 0.001 0.19 0.07, 0.50 0.0013
10 48.8 (20/41) 12.0 (6/50) 7.6 (4/53) 0.001 0.14 0.05, 0.41 0.001 0.09 0.03, 0.28 0.001
14 31.7 (13/41) 4.1 (2/49) 7.4 (4/54) 0.003 0.09 0.02, 0.44 0.004 0.17 0.05, 0.58 0.0004
Asexual parasite prevalence by SBP1
3 39.5 (17/43) 36.7 (18/49) 30.8 (16/52) 0.783 0.89 0.38, 2.06 0.373 0.68 0.29, 1.59 0.6529
7 21.4 (9/42) 34.0 (17/50) 27.8 (15/54) 0.185 1.89 0.74, 4.84 0.477 1.41 0.55, 3.64 0.4047
10 26.8 (11/41) 32.0 (16/50) 24.5 (13/53) 0.591 1.28 0.52, 3.19 0.8 0.89 0.35, 2.25 0.692
14 34.2 (14/41) 46.9 (23/49) 35.2 (19/54) 0.22 1.71 0.73, 4.01 0.92 1.05 0.45, 2.46 0.36
Asexual parasite prevalence by REX1
3 9.3 (4/43) 14.3 (7/49) 9.6 (5/52) 0.465 1.63 0.44, 6.00 0.959 1.04 0.26, 4.13 0.6921
7 14.3 (6/42) 18.0 (9/50) 11.1 (6/54) 0.632 1.32 0.43, 4.06 0.642 0.75 0.22, 2.52 0.606
10 17.1 (7/41) 16.0 (8/50) 15.1 (8/53) 0.891 0.93 0.30, 2.81 0.795 0.86 0.29, 2.61 0.9669
14 19.5 (8/41) 14.3 (7/49) 16.7 (9/54) 0.51 0.69 0.23, 2.1 0.72 0.83 0.29, 2.36 0.8
Asexual parasite prevalence by PhISTb
3 0 (0/43) 4.1 (2/49) 5.8 (3/52) NA NA NA 0.697 0.7 0.11, 4.35 0.6948
7 0 (0/42) 4.0 (2/50) 3.7 (2/54) NA NA NA NA NA NA 0.9374
10 4.9 (2/41) 4.0 (2/52) 1.9 (1/53) 0.839 0.81 0.11, 6.03 0.43 0.38 0.03, 4.29 0.6943
14 0 (0/41) 8.2 (4/49) 3.7 (2/54) 0.35 2.31 0.40,13.21 NA NA NA 0.33
AL = artemether/lumefantrine; CI = conﬁdence interval; NA = not available; OR = odds ratio; PQ = primaquine.
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until the end of the study at day 14. The prevalence at days
7, 10, and 14 is higher for SBP1 (20–40%) compared with
REX1 (10–20%) and PHISTb (0–5%) (Table 2). This fraction
does not decrease in a time-dependent manner, and is sim-
ilar between study arms (Table 2). There was no statistically
signiﬁcant difference in mean asexual parasite density
between different time points for all markers except SBP1
(Figure 2J–L). The mean density of asexual parasites, quan-
tiﬁed by SBP1 qRT-PCR appeared to increase toward the
end of follow-up (Table 3) and was higher on day 14 com-
pared with days 7 and 10 (P < 0.001 and P < 0.01, respec-
tively). Parasite density determined by PHISTb expression,
however, was signiﬁcantly higher compared with SBP1-
determined densities (P = 0.03) (Figure 2L). This may be
due to the lower sensitivity of PHISTb, resulting in quantita-
tive data for higher parasite density samples only.
Persisting ring-stage trophozoite transcripts in relation
to posttreatment gametocyte carriage. In addition to our
in vitro assessments of ring-stage trophozoite transcripts in
mature gametocytes, we quantiﬁed the correlation between
gametocyte markers and our general parasite markers and
ring-stage trophozoite markers to explore the possible
contribution of persisting gametocytes to ring-stage tro-
phozoite transcripts. As anticipated, the gametocyte signal
correlated with the total parasite signal based on 18S DNA
and transcripts on all days, except at day 0 (Table 1). The
signal of ring-stage trophozoite markers was not correlated
with the gametocyte signal during the entire period of
follow-up, conﬁrming that they detect different parasite
populations. To further exclude the possibility of back-
ground expression by gametocytes contributing to the
asexual marker signal, we determined Pfs25 prevalence in
samples obtained at the different time points that were
positive for SBP1, REX1, or PHISTb (Figure 3). With the
exception of enrolment and day 3 postinitiation of treatment,
when themajority of individuals were gametocyte positive,26
a minority of SBP1-, REX1-, and PHISTb-positive samples
concurrently had gametocytes detected by Pfs25 qRT-PCR.
AsREX1 andPHISTb are highly speciﬁc for asexual parasites
with detection of gametocytes expression only at concen-
trations exceeding 105 parasites/mL, this suggests that
there is no relevant contribution of gametocytes to
trophozoite-speciﬁc signals posttreatment. In addition,
in samples where Pfs25 signal could not be detected, we
still detected total parasites with Pf18S DNA and RNA and
ring-stage trophozoite signals with the three markers
(SBP1, REX1, and PHISTb) (Figure 4A–E). Overall, 34.5%
(132/383) of samples that were negative for gametocytes
from day 3 after treatment onward were positive for one or
more of the erring-stage trophozoite markers (Table 4).
Corresponding parasite densities for samples without
gametocyte-speciﬁc Pfs25 signal at days 3, 7, 10, and 14
are depicted in Figure 4H–J, respectively.
Speciﬁcity of SBP1 for asexual parasite detection. The
agreement between ring-stage trophozoite detection by
SBP1, REX1, and PHISTb was determined in follow-up day
7–14 samples that were gametocyte negative (Table 4).
SBP1 was able to identify more individuals, 31.5% (109/
346), with trophozoite-speciﬁc transcripts compared with
REX1 and PHISTb, 13.3% (46/346) and 3.8% (13/346), res-
pectively. SBP1 qRT-PCR was positive for 89.3% (109/122)
of all samples with evidence of ring-stage trophozoites
by any of the three assays, the remaining samples being
detected only by REX1 (9.0%; 11/122) or PHISb (1.6%;
2/122). We observed moderate but highly signiﬁcant agree-
ment between positivity by SBP1 and REX1 (agreement =
75.4%, kappa = 0.33; P < 0.0001) and PHISTb and REX1
(agreement = 86.4%, kappa = 0.15; P < 0.001) and lower
TABLE 3
Asexual parasite densities estimated by SBP1 on days 7, 10, and 14 after initiation of treatment
Treatment arm Days since treatment N Median (25th–75th percentiles) P value
Combined 14 53 1,741.8 (805.4–6025.6)
10 41 668.3 (309.7–1710.0) 0.0062
7 43 1,074 (323.4–2,275.1) 0.0162
AL 14 10 1,706.1 (1,081.4–2,296.1)
10 5 447.7 (291.7–937.6) 0.1171
7 8 817 (308.1–2,895.1) 0.778
AL + 0.25 mg PQ 14 22 2,230.8 (409.3–3,033.9)
10 20 670 (439.6–1,565.1) 0.1341
7 17 1,074 (339.6–1,798.9) 0.2345
AL + 0.40 mg PQ 14 21 1,990.7 (977.2–10,568.2)
10 16 887.5 (220.6–2,338.9) 0.0385
7 18 1,087.9 (282.5–1,584.9) 0.0408
AL= artemether/lumefantrine;N = number of samples positive for SBP1; PQ= primaquine; SBP1 = skeleton-binding protein 1. Density is expressed as estimated number of parasites permilliliter
of blood. The P value reﬂects the difference in density between day 14 and days 7 and 10.
FIGURE 3. Pfs25 prevalence in samples obtained at the different
time points that were positive for skeleton-binding protein 1 (SBP1),
ring-exported protein 1 REX1, or PHISTb. Bar graphs indicate the
relative gametocytes signal on day 0 vs. days 2, 3, 7, 10, and 14 after
initiation of treatment among samples that were found positive with
the three targets. Shading of bars indicates days since the start of
treatment (days 0–14), dark to light colors. Error bars indicate the
upper limit of the 95% conﬁdence interval of a binomial distribution.
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agreement between SBP1 and PHISTb (agreement = 71.1%,
kappa = 0.12; P < 0.0001) (Table 4).
DISCUSSION
Herein, we examined the sensitivity and stage speciﬁcity
of ﬁve markers (RESA, Hyp8, SBP1, REX1, and PHISTb) for
ring-stage trophozoites alongside several markers of total
parasitemia and gametocytemia. Our assays highlight the
complexity of interpreting RNA transcript data in clinical trial
samples. Our combination of in vitro time series and an in vivo
comparison of markers for the evaluation of an antimalarial
drug trial indicates that in a proportion of patients, ring-stage
trophozoite transcripts persist for 14 days after treatment with
ACTs plus different doses of primaquine.
ACTs rapidly reduce the asexual parasite biomass that is
present on clinical presentation with P. falciparum malaria.
Nevertheless, clinical trials have reported molecular signals
indicativeof persistence of asexual stageparasites for several
weeks.4,27–29 It is currently unclear whether these are true
indications of persisting asexual parasites and, until now,
artemisinin resistance has not been demonstrated in
Africa.30 Before the current study, the stage speciﬁcity of
these markers had not been rigorously examined with, for
example, conﬂicting evidence on the stage speciﬁcity of
SBP1.4 At present, there is no consensus on the value of
molecular tools to detect asexual parasites with high sen-
sitivity and speciﬁcity or interpretation of RNA transcripts
after antimalarial treatment.4 The sensitivity of pathogen
detection by molecular assays depends on the blood vol-
ume examined, the target, and assay efﬁciency.31 Although
RNA targets may be unstable and particularly prone to
contamination challenges,32 the detection of abundant
RNA transcripts allows highly sensitive stage-speciﬁc de-
tection of parasites.
Our in vitro experiments conﬁrm that DNA targets and
RNA transcripts of the 18S RNA gene are abundantly
present in both asexual parasites and gametocytes.25
FIGURE 4. Persisting parasite signal in the absence of gametocytemia in clinical trial samples. Prevalence of (A–B) total parasites and (C–E) ring-
stage trophozoites of clinical malaria trial samples that was negative for gametocyte transcripts (Pfs25). Presented in the bar graphs is the
prevalence of the signal with the differentmarkers in different days since treatment, in the three treatment arms. (F–J) Box plots indicate themedian,
25th and 75th percentile parasite densities (Log10 parasites/mL) of the markers in the three treatments arms. Whiskers indicate the 5th and 95th
percentiles. The three treatment groups are presented on the x axis: AL = only artemether–lumefantrine, 0.25 = AL + 0.25 mg/kg primaquine, and
0.40 = AL + 0.40mg/kg primaquine. Shading of bars and whiskers indicates days since the start of treatment (days 3–14), dark to light colors. Error
bars indicate the upper limit of the 95% conﬁdence interval of a binomial distribution.
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Posttreatment persistence of 18S DNA or RNA in peripheral
blood can thus be a consequence of the presence of both
trophozoites and gametocytes. The faster decline in the
prevalence of both Pf18S DNA and RNA in the groups that
received primaquine treatment is thus likely to be due to a
faster clearance of gametocytes following primaquine.15,33
This is supported by a decrease in Pfs25-based gameto-
cyte prevalence, which was signiﬁcantly lower in the
primaquine-treated groups at days 7, 10, and 14 post-
initiation of treatment.15 We found detectable signals of the
mature gametocytes stage-speciﬁc marker, Pfs25, in both
early and late ring-stage trophozoites when these asexual
parasites were present at densities ³ 106 parasites/mL in
vitro. Very low levels of Pfs25 mRNA were previously re-
ported in synchronous asexual parasite culture.28 Our
ﬁndings suggest that high asexual parasitemia may be ac-
companied by a false positive Pfs25 gametocyte signal.
This may lead to overestimations of baseline gametocyte
prevalence in clinical malaria cases that typically have
higher parasite densities but is unlikely to affect estimates
of posttreatment gametocyte dynamics when the asexual
parasite biomass is typically reduced by > 99%within days
after initiation of treatment.34
Our work conﬁrms that gametocytes commonly persist in
low concentrations for several weeks after treatment with
ACT or ACT with primaquine.6,35 This illustrates the neces-
sity to develop molecular assays that speciﬁcally detect
asexual parasites against a background of persisting ga-
metocytes that are epidemiologically relevant but not asso-
ciated with malaria pathogenesis or treatment failure.
Understanding andminimizing the impact of gametocytemia
on asexual parasite detection is essential to allow molecular
assays to support the interpretation of drug efﬁcacy in clin-
ical trials. We thus aimed to identify gene targets with neg-
ligible transcript levels in gametocytes but sensitive
detection of ring-stage trophozoites. Our selection of
markers included two previously reported13,14 and newly
identiﬁed markers. SBP1, REX1, and PHISTb were consid-
ered the most promising candidates based on their perfor-
mance in tightly synchronized in vitro culture material. Our
criteria included detectability of asexual parasites at den-
sities below 1,000 parasites/mL, the approximate detection
threshold for nested PCR or qPCR.31 Although the exact
lower limit of detection is difﬁcult to extrapolate from in vitro
studies to ﬁeld settings, our approach allowed comparison
of target genes and primer sequences for these genes.
Among the three candidates that were promising in
in vitro experiments, SBP1 was the most sensitive4,14 but
also showed the most pronounced expression in stage V
gametocytes. The other two newly identiﬁed markers, REX1
and PHISTb, showed high speciﬁcity for ring-stage tropho-
zoites; as only gametocyte densities ³ 106 gametocytes/mL
were detectable. Gametocyte densities in symptomatic
and asymptomatic infections are typically below 104
gametocytes/mL.36,37 If transcript levels are comparable
between in vitro-cultured parasites and natural infections, it
is thus unlikely that a positive signal in REX1 and PHISTb
qRT-PCR assays is caused by gametocytes in natural in-
fections, with a possible exception for rare high-density ga-
metocyte carriers. However, this increased speciﬁcity of
REX1 and PHISTb compared with SBP1 is challenged by a
lower sensitivity: SBP1 was able to detect lower concentra-
tions of asexual parasites compared with REX1 and PHISTb
based in in vitro experiments.
SBP1, REX1, and PHISTb were used to investigate the
presence of persisting asexual parasites in a clinical trial with
high treatment efﬁcacy and no asexual parasites detected by
microscopy beyond day 2 after initiation of treatment.15 All
three markers suggested that low densities of asexual par-
asites persisted after treatment. We chose a highly conser-
vative approach to minimize the chances of a contribution of
gametocytes to this ﬁnding. After excluding all Pfs25-
positive samples, and thereby all samples with > 0.1 game-
tocytes/μL, 43.2% (n/N) of samples remained positive for the
different markers on day 14 postinitiation of treatment. SBP1
was the most sensitive of our tested markers for detecting
ring-stage trophozoites with low to moderate agreement
with PHISTb and REX1 assays. An important caveat is that
our markers were selected based on expression in a single
laboratory-adapted parasite line, NF54. Although we pre-
viously assessed SBP1 transcript levels in 3D74 and Pfs25
transcript levels in NF54, NF135, and NF166 parasites38 and
found highly comparable levels between parasite isolates,
this does not mean that in vitro expression can be directly
extrapolated to expression in in vivo samples. Our quanti-
tative approachmay thus be affected by possible differences
between in vitro-cultured parasites and patient samples. In
future studies that use transcripts for parasite quantiﬁcation,
comparing expression proﬁles of target genes between
parasite strains and from parasites extracted in vivo can
address this uncertainty.
It is currently unknown whether our ring-stage tropho-
zoite transcripts represent viable malaria parasites and
whether mRNA transcripts may linger in the circulation after
asexual parasites have successfully been cleared. Injection
of killed Plasmodium chabaudi parasites directly into the
bloodstream or parasite remnants derived from parasites
cleared under natural conditions do not contribute to a
signal that is investigated with DNA-based PCR,39 impli-
cating that DNA derived from dead parasites circulates for
TABLE 4
Agreement between SBP1, REX1, and PHISTb for detecting asexual ring-stage parasite prevalence
SBP1 PHISTb
Positive Negative Positive Negative
REX1 Positive 10.1 (35/346) 3.2 (11/346) 1.7 (6/346) 11.6 (40/346)
Negative 21.4 (74/346) 65.3 (226/346) 2.0 (7/346) 84.7 (293/346)
PhISTb Positive 3.2 (11/346) 0.6 (2/346)
Negative 28.3 (98/346) 67.9 (235/346)
REX1 = ring-exported protein 1; SBP1 = skeleton-binding protein 1. Observations from days 7, 10, and 14 are combined to give one denominator. Presented is the percentage of samples that is
positive for a given marker (n/N).
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less than 48 hours. This same study, however, reported that
live but drug-damaged parasites (which would be unable to
initiate an infection when re-inoculated) may contribute to a
positive PCR signal in mice that were infected with
P. chabaudi and treatedwith antimalarial drug, up until days
13–16. On the other hand, in other diseases such as
Leishmania it was demonstrated that DNA is rapidly de-
graded following parasite death so that PCR detection in-
dicates viable cells.40
In malaria, parasites are removed by circulating and re-
ticuloendothelial phagocytes,41 removing parasite nuclear
material from the circulation. ACTs activate the host system,
mainly spleen, for aprocesscalled “pitting” to facilitate the rapid
clearance of asexual parasites.42,43 Taken together, these ob-
servations suggest that nonviable cells are unlikely to give RT-
PCR–positive signals. Arguing against the suggestion of viable
parasitesbeingdetectedbyourasexualmarkers is theﬁnding in
oneUgandanstudy thatSBP1 transcriptswerenotpredictiveof
treatment failure during 28 days of follow-up4 or microscopy
detectable rises in parasite density.33 We did, however, ﬁnd
indications that parasite density as quantiﬁed by SBP1 qRT-
PCR increased in individuals on day 14, a moment that
protective plasma concentrations of lumefantrine wane.44
This ﬁnding has to be interpreted with caution since no
treatment failure was observed. Longer periods of follow-up
may be needed to examine this. In addition, ex vivo parasite
culture from posttreatment blood samples may provide
evidence on the viability of the low-density parasite pop-
ulations whose presence our RNA-based assays suggests.
We aimed at elucidating stage-speciﬁc parasite dynamics
after antimalarial treatment using an array of quantitative
molecular assays. The high abundance and persistence of
18S RNA transcripts renders this target uninformative to in-
terpret treatment efﬁcacy. Our ﬁndings also demonstrate the
complexity of interpreting qRT-PCR ﬁndings since none of the
examined targets was exclusively transcribed in asexual
parasites or gametocytes. Three targets that show high
speciﬁcity for ring-stage trophozoites, and have only low
levels of transcripts in mature gametocytes, all indicate per-
sisting transcripts until day 14 postinitiation of treatment. Our
duration of follow-up was chosen to inform the game-
tocytocidal properties of the different antimalarials15 and was
too short to determinewhether thepersistenceof trophozoite-
speciﬁc transcripts was associated with subsequent recru-
descence of infections,45 de novo production of gametocytes
or enhanced transmission potential.27 Our study has dem-
onstrated the strength and weaknesses of several asexual
parasite targets for epidemiological and clinical studies.
Future studies should conﬁrm their sensitivity in natural
infections and determine the relevance of persisting parasite
transcripts after antimalarial treatment.
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